{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:26:52Z","timestamp":1793824012638,"version":"4.6.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Nippon Boehringer Ingelheim Co., Ltd. JST SPRING (grant number JPMJSP2110) JSPS KAKENHI"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Brain metastases (BrMs) in non-small cell lung cancer (NSCLC) respond poorly to anti-PD-1 monotherapy, but the underlying immune resistance remains incompletely defined. Here we integrate clinical outcome analyses, paired human tissue profiling and syngeneic mouse models to characterize the BrM immune microenvironment. Clinical analyses suggest improved intracranial disease control with nivolumab plus ipilimumab compared with nivolumab alone. Paired human specimens show that BrMs contain fewer cytotoxic T lymphocytes (CTLs) and tertiary lymphoid structures (TLSs) than primary tumors, defining an immune-excluded phenotype. A syngeneic BrM model recapitulates this phenotype and resists anti-PD-1 monotherapy, whereas combined anti-PD-1 and anti-CTLA-4 blockade suppresses tumor growth and prolongs survival. Single-cell RNA sequencing, flow cytometry and immunofluorescence show increased CTL infiltration and effector function after combination therapy. CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell depletion abrogates therapeutic benefit, and combination therapy expands T follicular helper-like cells and induces TLS-like structures. These findings manifest increased adaptive immune response of dual checkpoint blockade in NSCLC BrMs.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-74782-7","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:01:42Z","timestamp":1783414902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7864-897X","authenticated-orcid":false,"given":"Kazutaka","family":"Hosoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5315-3751","authenticated-orcid":false,"given":"Hiroaki","family":"Ozasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5706-8300","authenticated-orcid":false,"given":"Takahiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Oi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Suminaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-2411","authenticated-orcid":false,"given":"Kentaro","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2152-2150","authenticated-orcid":false,"given":"Tomoko","family":"Funazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Ajimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4328-3042","authenticated-orcid":false,"given":"Takashi","family":"Nomizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Katsuragawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritaka","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2977-888X","authenticated-orcid":false,"given":"Shigeki","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6346-3999","authenticated-orcid":false,"given":"Yohei","family":"Mineharu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi","family":"Menju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-7341","authenticated-orcid":false,"given":"Akihiko","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4626-4645","authenticated-orcid":false,"given":"Yoshiki","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Wake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyohiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"74782_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"74782_CR2","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti, A. K., Klein, A. B., Cotarla, I., Seal, B. & Chou, E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 7, 1824\u20131832 (2021).","journal-title":"JAMA Oncol."},{"key":"74782_CR3","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","volume":"38","author":"PW Sperduto","year":"2020","unstructured":"Sperduto, P. W. et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J. Clin. Oncol. 38, 3773 (2020).","journal-title":"J. Clin. Oncol."},{"key":"74782_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.12.005","volume":"162","author":"A Steindl","year":"2022","unstructured":"Steindl, A. et al. Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. Eur. J. Cancer 162, 170\u2013181 (2022).","journal-title":"Eur. J. Cancer"},{"key":"74782_CR5","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1111\/1759-7714.13557","volume":"11","author":"T Tozuka","year":"2020","unstructured":"Tozuka, T. et al. Poor efficacy of anti-programmed cell death-1\/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases. Thorac. Cancer 11, 2465\u20132472 (2020).","journal-title":"Thorac. Cancer"},{"key":"74782_CR6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi, H. A. et al. Combined nivolumab and ipilimumab in melanoma metastatic to the Brain. New Engl. J. Med. 379, 722\u2013730 (2018).","journal-title":"New Engl. J. Med."},{"key":"74782_CR7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long, G. V. et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 19, 672\u2013681 (2018).","journal-title":"Lancet Oncol."},{"key":"74782_CR8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jtho.2023.04.021","volume":"18","author":"M Reck","year":"2023","unstructured":"Reck, M. et al. Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and baseline brain metastases from CheckMate 227 part 1. J. Thorac. Oncol. 18, 1055\u20131069 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"74782_CR9","doi-asserted-by":"publisher","first-page":"115052","DOI":"10.1016\/j.ejca.2024.115052","volume":"212","author":"Y Tsuchiya-Kawano","year":"2024","unstructured":"Tsuchiya-Kawano, Y. et al. Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: a multicenter single-arm phase 2 trial (NIke, LOGiK 2004). Eur. J. Cancer 212, 115052 (2024).","journal-title":"Eur. J. Cancer"},{"key":"74782_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"74782_CR11","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke, L. et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2, 794\u2013802 (2021).","journal-title":"Nat. Cancer"},{"key":"74782_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5214-8","volume":"19","author":"R Kim","year":"2019","unstructured":"Kim, R. et al. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. BMC Cancer 19, 19 (2019).","journal-title":"BMC Cancer"},{"key":"74782_CR13","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1158\/1078-0432.CCR-19-2184","volume":"26","author":"K Pocha","year":"2020","unstructured":"Pocha, K. et al. Surfactant expression defines an inflamed subtype of lung adenocarcinoma brain metastases that correlates with prolonged survival. Clin. Cancer Res. 26, 2231\u20132243 (2020).","journal-title":"Clin. Cancer Res."},{"key":"74782_CR14","volume":"2","author":"D Ikarashi","year":"2021","unstructured":"Ikarashi, D. et al. Comparison of tumor microenvironments between primary tumors and brain metastases in patients with NSCLC. JTO Clin. Res. Rep. 2, 100230 (2021).","journal-title":"JTO Clin. Res. Rep."},{"key":"74782_CR15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s43018-023-00566-3","volume":"4","author":"V Wischnewski","year":"2023","unstructured":"Wischnewski, V. et al. Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation. Nat. Cancer 4, 908\u2013924 (2023).","journal-title":"Nat. Cancer"},{"key":"74782_CR16","doi-asserted-by":"publisher","unstructured":"Zuccato, J. A. et al. Prediction of brain metastasis development with DNA methylation signatures. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03286-y (2024).","DOI":"10.1038\/s41591-024-03286-y"},{"key":"74782_CR17","doi-asserted-by":"publisher","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","volume":"115","author":"D Taggart","year":"2018","unstructured":"Taggart, D. et al. Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking. Proc. Natl. Acad. Sci. USA 115, E1540\u2013E1549 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74782_CR18","doi-asserted-by":"crossref","unstructured":"Phadke, M. S. et al. Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models. J. Immunother. Cancer 11, e007239 (2023).","DOI":"10.1136\/jitc-2023-007239"},{"key":"74782_CR19","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1016\/j.immuni.2024.09.003","volume":"57","author":"JM Messmer","year":"2024","unstructured":"Messmer, J. M. et al. T lymphocyte recruitment to melanoma brain tumors depends on distinct venous vessels. Immunity 57, 2688\u20132703 (2024).","journal-title":"Immunity"},{"key":"74782_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","volume":"7","author":"P Xing","year":"2019","unstructured":"Xing, P. et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J. Immunother. Cancer 7, 341 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"74782_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.lungcan.2023.01.006","volume":"177","author":"K O\u2019Byrne","year":"2023","unstructured":"O\u2019Byrne, K. et al. Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: a systematic literature review and network meta-analysis. Lung Cancer 177, 11\u201320 (2023).","journal-title":"Lung Cancer"},{"key":"74782_CR22","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00262-020-02840-0","volume":"70","author":"SG Song","year":"2021","unstructured":"Song, S. G. et al. Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape. Cancer Immunol. Immunother. 70, 2035\u20132048 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"74782_CR23","doi-asserted-by":"publisher","first-page":"1305644","DOI":"10.3389\/fimmu.2023.1305644","volume":"14","author":"S Najjary","year":"2023","unstructured":"Najjary, S., de Koning, W., Kros, J. M. & Mustafa, D. A. M. Unlocking molecular mechanisms and identifying druggable targets in matched-paired brain metastasis of breast and lung cancers. Front. Immunol. 14, 1305644 (2023).","journal-title":"Front. Immunol."},{"key":"74782_CR24","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1158\/0008-5472.CAN-18-3560","volume":"79","author":"A Jim\u00e9nez-S\u00e1nchez","year":"2019","unstructured":"Jim\u00e9nez-S\u00e1nchez, A., Cast, O. & Miller, M. L. Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods. Cancer Res. 79, 6238\u20136246 (2019).","journal-title":"Cancer Res."},{"key":"74782_CR25","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1126\/science.286.5447.2098","volume":"286","author":"JG Cyster","year":"1999","unstructured":"Cyster, J. G. Chemokines and cell migration in secondary lymphoid organs. Science 286, 2098\u20132102 (1999).","journal-title":"Science"},{"key":"74782_CR26","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.ccell.2024.07.006","volume":"42","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. Cancer Cell 42, 1370\u20131385 (2024).","journal-title":"Cancer Cell"},{"key":"74782_CR27","doi-asserted-by":"publisher","first-page":"e005531","DOI":"10.1136\/jitc-2022-005531","volume":"10","author":"X Sun","year":"2022","unstructured":"Sun, X. et al. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. J. Immunother. Cancer 10, e005531 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"74782_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12026-025-09595-9","volume":"73","author":"B Han","year":"2025","unstructured":"Han, B., Deng, J. & Fan, R. Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in lung adenocarcinoma. Immunol. Res. 73, 40 (2025).","journal-title":"Immunol. Res."},{"key":"74782_CR29","doi-asserted-by":"publisher","unstructured":"Guo, Z. et al. Tertiary lymphoid structures signature predicts prognosis and clinical benefits from adjuvant chemotherapy and PD-L1 blockade in colorectal adenocarcinoma. Int. J. Surg. https:\/\/doi.org\/10.1097\/JS9.0000000000002568 (2025).","DOI":"10.1097\/JS9.0000000000002568"},{"key":"74782_CR30","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.immuni.2019.10.006","volume":"51","author":"W Xu","year":"2019","unstructured":"Xu, W. et al. The transcription factor Tox2 drives T follicular helper cell development via regulating chromatin accessibility. Immunity 51, 826\u2013839 (2019).","journal-title":"Immunity"},{"key":"74782_CR31","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.it.2021.02.002","volume":"42","author":"J Choi","year":"2021","unstructured":"Choi, J. & Crotty, S. Bcl6-mediated transcriptional regulation of follicular helper T cells (TFH). Trends Immunol. 42, 336\u2013349 (2021).","journal-title":"Trends Immunol."},{"key":"74782_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23324-4","volume":"12","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat. Commun. 12, 2965 (2021).","journal-title":"Nat. Commun."},{"key":"74782_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.immuni.2021.12.007","volume":"55","author":"RA Chaurio","year":"2022","unstructured":"Chaurio, R. A. et al. TGF-\u03b2-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity 55, 115\u2013128 (2022).","journal-title":"Immunity"},{"key":"74782_CR34","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1073\/pnas.1414576112","volume":"112","author":"CJ Wang","year":"2014","unstructured":"Wang, C. J. et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc. Natl. Acad. Sci. USA 112, 524 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74782_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24347-7","volume":"12","author":"L van Hooren","year":"2021","unstructured":"van Hooren, L. et al. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. Nat. Commun. 12, 4127 (2021).","journal-title":"Nat. Commun."},{"key":"74782_CR36","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ccell.2023.04.010","volume":"41","author":"M Ramachandran","year":"2023","unstructured":"Ramachandran, M. et al. Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell 41, 1134\u20131151 (2023).","journal-title":"Cancer Cell"},{"key":"74782_CR37","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1016\/j.jtho.2017.04.027","volume":"12","author":"T Funazo","year":"2017","unstructured":"Funazo, T., Nomizo, T. & Kim, Y. H. Liver metastasis is associated with poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. J. Thorac. Oncol. 12, e140\u2013e141 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"74782_CR38","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJM199908123410703","volume":"341","author":"A Aup\u00e9rin","year":"1999","unstructured":"Aup\u00e9rin, A. et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. New Engl. J. Med. 341, 476\u2013484 (1999).","journal-title":"New Engl. J. Med."},{"key":"74782_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12798-2","volume":"24","author":"K Hosoya","year":"2024","unstructured":"Hosoya, K. et al. Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients. BMC Cancer 24, 1030 (2024).","journal-title":"BMC Cancer"},{"key":"74782_CR40","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"74782_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinform. 14, 7 (2013).","journal-title":"BMC Bioinform."},{"key":"74782_CR42","doi-asserted-by":"crossref","unstructured":"Sturm, G., Finotello, F. & List, M. Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data. in (ed. Boegel, S.) Bioinformatics for Cancer Immunotherapy: Methods and Protocols, 223\u2013232 (Springer, 2020).","DOI":"10.1007\/978-1-0716-0327-7_16"},{"key":"74782_CR43","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/0008-5472.CAN-17-1987","volume":"78","author":"K Sili\u0146a","year":"2018","unstructured":"Sili\u0146a, K. et al. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 78, 1308\u20131320 (2018).","journal-title":"Cancer Res."},{"key":"74782_CR44","doi-asserted-by":"publisher","first-page":"e005539","DOI":"10.1136\/jitc-2022-005539","volume":"11","author":"M He","year":"2023","unstructured":"He, M. et al. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer. J. Immunother. Cancer 11, e005539 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"74782_CR45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nprot.2015.140","volume":"11","author":"T Sakuma","year":"2016","unstructured":"Sakuma, T., Nakade, S., Sakane, Y., Suzuki, K.-I. T. & Yamamoto, T. MMEJ-assisted gene knock-in using TALENs and CRISPR-Cas9 with the PITCh systems. Nat. Protoc. 11, 118\u2013133 (2016).","journal-title":"Nat. Protoc."},{"key":"74782_CR46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1126\/science.aaq1067","volume":"359","author":"S Iwano","year":"2018","unstructured":"Iwano, S. et al. Single-cell bioluminescence imaging of deep tissue in freely moving animals. Science 359, 935\u2013939 (2018).","journal-title":"Science"},{"key":"74782_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/srep05400","volume":"4","author":"T Sakuma","year":"2014","unstructured":"Sakuma, T., Nishikawa, A., Kume, S., Chayama, K. & Yamamoto, T. Multiplex genome engineering in human cells using all-in-one CRISPR\/Cas9 vector system. Sci. Rep. 4, 5400 (2014).","journal-title":"Sci. Rep."},{"key":"74782_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36874-3","volume":"9","author":"Z Liu","year":"2019","unstructured":"Liu, Z. et al. Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method. Sci. Rep. 9, 622 (2019).","journal-title":"Sci. Rep."},{"key":"74782_CR49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-25-3425","author":"T Tsuji","year":"2025","unstructured":"Tsuji, T. et al. Microglia display heterogeneous initial responses to disseminated tumor cells. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-3425 (2025).","journal-title":"Cancer Res."},{"key":"74782_CR50","doi-asserted-by":"publisher","unstructured":"Ozawa, T. & James, C. D. Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J. Vis. Exp. 1986, https:\/\/doi.org\/10.3791\/1986 (2010).","DOI":"10.3791\/1986"},{"key":"74782_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/cpch.14","volume":"8","author":"J-R Lin","year":"2016","unstructured":"Lin, J.-R., Fallahi-Sichani, M., Chen, J.-Y. & Sorger, P. K. Cyclic immunofluorescence (CycIF), a highly multiplexed method for single-cell imaging. Curr. Protoc. Chem. Biol. 8, 251\u2013264 (2016).","journal-title":"Curr. Protoc. Chem. Biol."},{"key":"74782_CR52","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.31657","volume":"7","author":"J-R Lin","year":"2018","unstructured":"Lin, J.-R. et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. eLife 7, e31657 (2018).","journal-title":"eLife"},{"key":"74782_CR53","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421 (2016).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74782-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74782-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74782-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:01:54Z","timestamp":1783414914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74782-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74782"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74782-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hiroaki Ozasa received research funding from Nippon Boehringer Ingelheim Co., Ltd. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Hiroaki Ozasa also received honoraria from AstraZeneca K.K., MSD K.K., Pfizer Japan Inc., Novartis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Sanofi K.K., and Eli Lilly Japan K.K.\u3000Kentaro Tsuji received honoraria from Chugai Pharmaceutical Co., Ltd.\u3000Yoshiki Arakawa received grants to his institute from Philips, Otsuka, Chugai, Nihon Medi-Physics, Daiichi Sankyo, Stryker, Eisai, Japan Blood Products Organization, Ono Pharmaceutical, Taiho Pharma, Sumitomo Dainippon Pharma, Astellas Pharma, Incyte Biosciences, and Servier. Yoshiki Arakawa also received honoraria from Nippon Kayaku, Novocure, UCB Japan, Ono Pharmaceutical, Brainlab, Merck, Chugai, Eisai, Daiichi Sankyo, Carl Zeiss, Nihon Medi-Physics, and Stryker.\u3000Toyohiro Hirai received research grants from TAIHO Pharmaceutical Co., Ltd. and CHUGAI Pharmaceutical Co., Ltd. Toyohiro Hirai also received honoraria from Nippon Boehringer Ingelheim and AstraZeneca K.K. The other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5681"}}